Cidara Therapeutics, Inc. (CDTX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in San Diego, CA, United States. Der aktuelle CEO ist Jeffrey L. Stein.
CDTX hat IPO-Datum 2015-04-15, 38 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $5.61B.
Cidara Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing long-acting anti-infective treatments for infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel echinocandin antifungal designed to treat and prevent invasive fungal infections such as candidemia and invasive candidiasis, which carry high mortality rates. Cidara also leverages its Cloudbreak platform to develop conjugate therapies for preventing and treating viral infections, including influenza, RSV, HIV, and COVID-19. Founded in 2012 and based in San Diego, California, the company was formerly known as K2 Therapeutics before rebranding to Cidara Therapeutics in 2014.
